BACKGROUND: This study was conducted to evaluate the durability of clevudine-induced viral response after the withdrawal of treatment. METHODS: Patients who showed a complete response [alanine aminotransferase (ALT) normalization and hepatitis B virus (HBV) DNA <4,700 copies/mL for hepatitis B envelope antigen (HBeAg)-negative patients; ALT normalization, HBV DNA <4,700 copies/mL, and HBeAg seroconversion for HBeAg-positive patients] in the previous clevudine phase III trials were followed for an additional 96 weeks without any treatment for hepatitis B. RESULTS: Of the 63 patients in the study cohort, 73% and 35% of the patients had HBV DNA <141,500 and <4,700 copies/mL, respectively, and 75% of the patients had normal ALT at the end of follow-up. HBeAg seroconversion was maintained in 81% of the patients and hepatitis B surface antigen (HBsAg) loss occurred in 3 patients. Continued HBsAg titer decrease (-0.5 log IU/mL) was observed in the sustained viral responders, suggesting the reduction of covalently closed circular DNA in hepatocytes. CONCLUSIONS: The clevudine-induced viral response was durable in the majority of patients for 2 years after the withdrawal of treatment.
BACKGROUND: This study was conducted to evaluate the durability of clevudine-induced viral response after the withdrawal of treatment. METHODS:Patients who showed a complete response [alanine aminotransferase (ALT) normalization and hepatitis B virus (HBV) DNA <4,700 copies/mL for hepatitis B envelope antigen (HBeAg)-negative patients; ALT normalization, HBV DNA <4,700 copies/mL, and HBeAg seroconversion for HBeAg-positive patients] in the previous clevudine phase III trials were followed for an additional 96 weeks without any treatment for hepatitis B. RESULTS: Of the 63 patients in the study cohort, 73% and 35% of the patients had HBV DNA <141,500 and <4,700 copies/mL, respectively, and 75% of the patients had normal ALT at the end of follow-up. HBeAg seroconversion was maintained in 81% of the patients and hepatitis B surface antigen (HBsAg) loss occurred in 3 patients. Continued HBsAg titer decrease (-0.5 log IU/mL) was observed in the sustained viral responders, suggesting the reduction of covalently closed circular DNA in hepatocytes. CONCLUSIONS: The clevudine-induced viral response was durable in the majority of patients for 2 years after the withdrawal of treatment.
Authors: J H Kim; H J Yim; E S Jung; Y K Jung; J H Kim; Y S Seo; J E Yeon; H S Lee; S H Um; K S Byun Journal: J Viral Hepat Date: 2011-04 Impact factor: 3.728
Authors: Won Young Tak; Soo Young Park; Chang Min Cho; Min Kyu Jung; Seong Woo Jeon; Young Oh Kweon; Ji Young Park; Yoon Kyung Sohn Journal: J Hepatol Date: 2010-04-18 Impact factor: 25.083
Authors: Byung Kook Kim; Jeeyoung Oh; So Young Kwon; Won Hyeok Choe; Soon Young Ko; Kyoung Hoon Rhee; Tae Ho Seo; So Dug Lim; Chang Hong Lee Journal: J Hepatol Date: 2009-05-28 Impact factor: 25.083
Authors: Jung Im Seok; Dong Kuck Lee; Chang Hyeong Lee; Min Su Park; Sun Young Kim; Hyang-Sook Kim; Hee-Young Jo; Chang Hun Lee; Dae-Seong Kim Journal: Hepatology Date: 2009-06 Impact factor: 17.425
Authors: C K Chu; T Ma; K Shanmuganathan; C Wang; Y Xiang; S B Pai; G Q Yao; J P Sommadossi; Y C Cheng Journal: Antimicrob Agents Chemother Date: 1995-04 Impact factor: 5.191
Authors: Myeong Jun Song; Do Seon Song; Hee Yeon Kim; Sun Hong Yoo; Si Hyun Bae; Jong Young Choi; Seung Kew Yoon; Yong-Han Paik; June Sung Lee; Hyun Woong Lee; Hyung Joon Kim Journal: World J Gastroenterol Date: 2012-11-21 Impact factor: 5.742
Authors: Byung Kook Kim; Soon Young Ko; So Young Kwon; Eugene Park; Jeong Han Kim; Won Hyeok Choe; Chang Hong Lee Journal: Hepat Mon Date: 2013-04-01 Impact factor: 0.660
Authors: Won Young Tak; Jin Mo Yang; Byung Ik Kim; Soon Koo Baik; Gab Jin Cheon; Kwan Soo Byun; Do Young Kim; Byung Chul Yoo Journal: Hepatol Int Date: 2014-05-25 Impact factor: 6.047